Joseph Curry
Associate Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (17)
Figure s4. Gene set enrichment analysis (GSEA) across baseline responder vs. nonresponder comparisons and baseline vs. post-treatment analyses in the durvalumab-metformin clinical trial and other clinical trial cohorts. GSEA was performed to assess differences between baseline responders and nonresponders, as well as baseline vs. post-treatment samples
Year:
2025
Purpose: Immune checkpoint inhibitors (ICI) have demonstrated clinical benefit in head and neck squamous cell carcinoma (HNSCC); however, single-agent efficacy is limited, leaving significant unmet needs. Metformin may synergize with ICIs, offering promise to improve response rates. We leveraged multiomic data from a randomized, presurgical neoadjuvant trial (NCT03618654) evaluating a single infusion of the anti–PD-L1 ICI durvalumab with or without daily, standard dose metformin in previously untreated, nondiabetic patients with HNSCC to understand predictors of response and the effect of combination therapy. Patients and Methods: Clinical, pathologic, and correlative data were analyzed to investigate response and resistance mechanisms. We present an in-depth multiomic analysis of primary tumor specimens to study treatment response/resistance in human papillomavirus–positive HNSCC. Results: Baseline samples revealed that myofibroblastic cancer-associated fibroblast and extracellular matrix signatures were enriched in durvalumab plus metformin nonresponders, which were localized to the leading tumor edge on spatial transcriptomics. In contrast, baseline responder samples were enriched for the Langerhans-like dendritic cell (DC) state and IFN signatures. Treatment increased intratumoral CD8 + T-cell and IFN signatures and peripheral blood CCL2 levels. Responders demonstrated macrophage and DC enrichment and antigen processing and presentation upregulation. Enrichment of cell cycle–related gene sets, specifically the MYC targets V1 hallmark gene set, correlated with nonresponse. Conclusions: Early response and resistance dynamics for durvalumab plus metformin in human papillomavirus–positive HNSCC reveal baseline extracellular matrix–myofibroblastic cancer-associated fibroblast as predictive of nonresponse. In contrast, responders were distinguished by baseline enrichment in the Langerhans-like DC state and posttreatment antigen-presenting gene sets.
Year:
2025
Figure s5. Baseline immune cell composition in responders and nonresponders across bulk, tumor, and stromal compartments & Immune cell deconvolution analysis in bulk tumor samples of responders and nonresponders before and after durvalumab-metformin treatment.
Year:
2025
Figure s11. Carcinoma ecotype differences at baseline and after treatment in HPV+ HNSCC responders and non-responders. This figure illustrates differences in carcinoma ecotype composition before and after treatment in HPV+ HNSCC patients
Year:
2025
Background Neck spasms or myoclonus are an underreported sequela of HNC treatment, often described following radiation. The frequency of neck spasm following neck dissection is unknown. Methods A phone survey was conducted of HNC patients following neck dissection to determine the incidence and severity of neck spasms using the Penn Spasm Frequency Scale and Neck Dissection Impairment Index. Demographic and treatment‐related factors were compared between those with and without neck spasms. Results 56/136 patients (41.2%) responded with 16 (28.6%) reporting neck spasms. Spasms ranged from mild to severe and were associated with a lower NDII score (85.62 vs. 90.44, p = 0.078) Neck spasms occurred irrespective of shoulder dysfunction due to cranial nerve 11 injury and were not associated with any patient or treatment‐related factors, including radiation therapy. Conclusions Neck spasms occur after neck dissection irrespective of radiation therapy or spinal accessory nerve injury with a negative impact on quality of life.
Year:
2025
Supplement Figure 3: Signature-based Biomarkers. A: Signature-Based biomarkers for HPV negative patients. B: Signature-based biomarkers for HPV positive patients. ‘Primary Path Response’ refers to analysis based on the pTR at the primary site alone. ‘Overall path response’ refers to analysis based on primary + lymph node response.
Year:
2025
Supplement Figure 1: Waterfall Plots. A: Degree of pathologic treatment response (pTR) at the lymph nodes. B: Degree of pathologic response at the primary site, stratifed by treatment arm. C: Degree of RECIST response of primary tumor site (yellow) and lymph nodes (purple), stratifed by treatment arm.
Year:
2025
Supplement Table 4A-4B: The following is a comprehensive list of the top 20 functional enrichments in the B cell (A) and CAF2 (B) gene sets utilizing STRING database to analyze protein-protein interaction pairs among the leading edge.
Year:
2025
Supplement Table 2A-2E: GSEA quantitative data for the B cell gene sets and CAF2 gene set for Post- vs Pre-treatments Responders vs Non responders. The following is a comprehensive list of supervised B-cell (A-C) and CAF (D-E) enrichment scores, normal enrichment scores, p-values, and q-values for the included gene sets.
Year:
2025
Supplementary Figure 2: Effect of IDO inhibitor BMS986205 on response rate and the tryptophan kynurenine pathway. A and B: IDO1 gene expression levels and tryptophan kynurenine pathway activity score, respectively, compared between baseline samples of responders (R) and non-responders (NR) on nivolumab + BMS986205 and nivolumab-only therapies. C: Tryptophan kynurenine pathway activity score compared between baseline and post-treatment samples of R and NR on nivolumab + BMS986205 and nivolumab-only therapies. - ns, *p
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Collaborators (19)
Andrew South
Oros Family Professor in Rare Skin Diseases
University of Wisconsin-Madison
Megan Roche
Thomas Jefferson University
Ramkrishna Mitra
Assistant Professor
Thomas Jefferson University
Nolan B. Seim
Assistant Professor
Ohio State University
David Cognetti
department of surgery thomas jefferson university hospital sidney kimmel medical college philadelphia university and tho
Tingting Zhan
Associate Professor
Thomas Jefferson University
Rita Axelrod
Professor
Thomas Jefferson University
George Prendergast
Professor, President & CEO
Lankenau Institute for Medical Research
Hushan Yang
Professor
Thomas Jefferson University
Benjamin Leiby
Professor
Thomas Jefferson University
Charalambos Solomides
Professor
Thomas Jefferson University
Rajanikanth Vadigepalli
Thomas Jefferson University
Scott W. Keith
Thomas Jefferson University
Larry Harshyne
Associate Professor
Thomas Jefferson University
Jennifer M. Johnson
Thomas Jefferson University
John R. Eisenbrey
Thomas Jefferson University
Ubaldo Martinez-Outschoorn
Associate Professor
Thomas Jefferson University
Stacey Gargano
Thomas Jefferson University Hospital
Adam J. Luginbuhl
-
Make your next move.
Prepare your application
Review drafts before you send them.